• Pulmotect Initiates Landmark Phase 2 Clinical Trial in Immunosuppressed Cancer Patients
• Pulmotect Raises $5.9M Series C Round Led by Fannin Partners
• Pulmotect Receives First Tranche of $8.9 Million from The State of Texas
• Pulmotect Awarded $8.9 Million from The State of Texas
• Pulmotect Provides Results from Two Randomized, Placebo Controlled Phase-2 Trials of PUL-042 Against COVID-19
• Pulmotect Reports Positive Topline Results from Randomized, Placebo Controlled Phase-2 Trial of PUL-042 against COVID-19
• Pulmotect Appoints William J. Noss III as Chief Financial Officer
• Pulmotect Awarded Up To $6M From Department of Defense to Complete Two COVID-19 Trials
• Pulmotect receives FDA approval to commence two Phase-2 trials targeting COVID-19
• Pulmotect’s PUL-042 Shows Promising Pre-Clinical Efficacy in Preventing Lethal Coronavirus Infection
• Dr. Colin Broom joins Pulmotect, Inc. as CEO
• AstraZeneca VP Kumar Srinivasan Joins Pulmotect, Inc. Board of Directors
• Pulmotect Announces Initial Close on $12 Million Series B
• Telephus Medical CEO Mark Benedyk Joins Pulmotect, Inc. Board of Directors
• Pulmotect Convenes Inaugural Scientific Advisory Board
• Pulmotect Selected to Exhibit at 2017 BIO International Convention “Innovation Zone”
• US China Innovation and Investment Summit Panel on Biopharmaceuticals to Feature Pulmotect CEO
• Pulmotect Completes Second Clinical Trial, Closes $1.75M Investment, Earns $1M NIH Award
• Pulmotect Awarded $3 Million NIH Grant to Fund Infection Prevention Drug Trials
• Pulmotect Completes Clinical Testing, Receives CPRIT Funding for Continued Development